pioglitazone has been researched along with Brain Vascular Disorders in 9 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to conduct a direct comparison of TZDs (pioglitazone and rosiglitazone) and their relationship to cardiovascular events (myocardial infarction [MI], angina, congestive heart failure [CHF], and cerebral vascular accident [CVA]) in Taiwanese patients with type 2 diabetes mellitus (DM)." | 3.77 | Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. ( Chang, YW; Chen, WL; Chou, CC; Kao, TW; Loh, CH; Wang, CC, 2011) |
| "Pioglitazone treatment rescued a third of these proteins, mainly those associated with oxidative stress, promotion of cerebrovascular vasocontractile tone, and vascular compliance." | 1.46 | Proteomic differences in brain vessels of Alzheimer's disease mice: Normalization by PPARγ agonist pioglitazone. ( Badhwar, A; Brown, R; Hamel, E; Haqqani, AS; Stanimirovic, DB, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, KC | 1 |
| Learman, CR | 1 |
| Baker, GB | 1 |
| Weaver, CL | 1 |
| Chung, PS | 1 |
| Kim, HG | 1 |
| Song, MS | 1 |
| Katsiki, N | 1 |
| Mikhailidis, DP | 1 |
| Inzucchi, SE | 1 |
| Viscoli, CM | 1 |
| Young, LH | 1 |
| Furie, KL | 1 |
| Gorman, M | 1 |
| Lovejoy, AM | 1 |
| Dagogo-Jack, S | 1 |
| Ismail-Beigi, F | 1 |
| Korytkowski, MT | 1 |
| Pratley, RE | 1 |
| Schwartz, GG | 1 |
| Kernan, WN | 1 |
| Pantoni, L | 1 |
| Badhwar, A | 1 |
| Brown, R | 1 |
| Stanimirovic, DB | 1 |
| Haqqani, AS | 1 |
| Hamel, E | 3 |
| Lai, SW | 1 |
| Lin, HF | 1 |
| Lin, CL | 1 |
| Liao, KF | 1 |
| Nicolakakis, N | 2 |
| Aboulkassim, T | 2 |
| Ongali, B | 1 |
| Lecrux, C | 1 |
| Fernandes, P | 1 |
| Rosa-Neto, P | 2 |
| Tong, XK | 2 |
| Aliaga, A | 1 |
| Wang, CC | 1 |
| Chen, WL | 1 |
| Kao, TW | 1 |
| Chang, YW | 1 |
| Loh, CH | 1 |
| Chou, CC | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cerebrovascular Reactivity (CVR) Assessed With Functional Near Infrared Spectroscopy (fNIRS) as a Biomarker of Traumatic Cerebrovascular Injury (TCVI) Measured Longitudinally After Acute TBI in Military Personnel[NCT04058132] | Phase 2 | 50 participants (Anticipated) | Interventional | 2019-08-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pioglitazone and Brain Vascular Disorders
| Article | Year |
|---|---|
Regulation of Diabetes: a Therapeutic Strategy for Alzheimer's Disease?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Astrocytes; Brain; Cerebrovascular Disorders; Diabetes Mel | 2019 |
8 other studies available for pioglitazone and Brain Vascular Disorders
| Article | Year |
|---|---|
Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.
Topics: Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; In | 2017 |
Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.
Topics: Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; In | 2017 |
Potential New Horizons for the Prevention of Cerebrovascular Diseases and Dementia.
Topics: Cerebrovascular Disorders; Dementia; Humans; Pioglitazone; Prediabetic State; Stroke | 2019 |
Proteomic differences in brain vessels of Alzheimer's disease mice: Normalization by PPARγ agonist pioglitazone.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Biomarkers; Blood | 2017 |
Long-term effects of pioglitazone on first attack of ischemic cerebrovascular disease in older people with type 2 diabetes: A case-control study in Taiwan.
Topics: Aged; Case-Control Studies; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Female; Humans; Hy | 2016 |
Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist.
Topics: Acetylcholine; Acetylcysteine; Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein | 2008 |
Intact memory in TGF-β1 transgenic mice featuring chronic cerebrovascular deficit: recovery with pioglitazone.
Topics: Aging; Animals; Antioxidants; Blotting, Western; Cerebrovascular Circulation; Cerebrovascular Disord | 2011 |
Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Cardiovascular Diseases; C | 2011 |